Search
Advice
Ask Value Research
Big Questions
Tax Q&A
The Plan
Columns
Econology
First Page
Generally Speaking
Guest Column
Mainstreet
Not Just Kidding
Of This & That...
Straight Talk
Taking Stock
The Chartist
Top of Mind
Fund Research
Category Watch
Fund Analysis
House Voice
IPO Analysis
Rating Radar
Stock Research
Data for Thought
Stock Advisor
Stock Analyst Choice
Stock Ideas
Stock Strategy
News & Commentary
Fund News
Fundwire
Marketwire
Newswire
Stockwire
Others
Advertorial
Book Review
First things...
Fund Focus
Fund Manager's View
Fundwise
How I did it
In Remembrance
Income Tax Know How
Insurance
Interview
Learning
Moneywise
Mutual Fund Sahi Hai
Omaha Live
SIP Sahi Hai
Special Report
Tax Saving Alternatives
Using Value Research Online
Words Worth

News & Views - Sun Pharmaceutical Inds.

Banking on a process driven approach, Mahesh Patil is an expert picker of growth opportunities |
Value funds have out-performed benchmark indices over the long-term as well as short-term |
Buybacks since March 2016 don't seem to indicate that companies are trying to save on the dividend tax |
Did you know that out of about 2,000 companies listed on the NSE, only five stand out as consistently high performers? Read about them here |
This comparison pits told old rivals against each other using MSCI India Indices. Time determines the answer |
Up to three qualified merchant bankers and selling brokers for 'attending, assisting and advising' on the SUUTI Holdings to be appointed. Click to read our view on the sale |
A dramatically low sales guidance stands in stark contrast to solid results for the March quarter |
We compared total returns on the S&P BSE Dividend Stability Index with the BSE Sensex, Nifty and other indices to find out whether the strategy really works |
Sun Pharma has fallen some 40 per cent from its 52-week highs. What ails the country's largest pharmaceutical company and what's ahead |
The firm is facing protests from its sales force for allegedly transferring and demoting some employees of Ranbaxy which it acquired last year |
Even though the USFDA created problems for large pharma companies, their smaller counterparts have been doing very well |
Increasing run-ins of pharmaceutical companies with the US FDA is a matter of concern |
Home | My Portfolio | ELSS | Funds | Investors' Hangout | Income | Insurance | Value Investing | Learn | Archive | Ask | We're Hiring | Subscribe | About Us | Log In | Free Sign Up